Aimee E Vozenilek1, Cassidy M R Blackburn1, Robert M Schilke1, Sunitha Chandran1, Reneau Castore2, Ronald L Klein3, Matthew D Woolard4. 1. Department of Microbiology and Immunology, Louisiana State University Health Sciences Center, Shreveport, LA, 71130, USA. 2. Feist-Weiller Cancer Center, Louisiana State University Health Sciences Center, Shreveport, LA, 71130, USA. 3. Department of Pharmacology, Toxicology and Neuroscience, Louisiana State University Health Sciences Center, Shreveport, LA, 71130, USA. 4. Department of Microbiology and Immunology, Louisiana State University Health Sciences Center, Shreveport, LA, 71130, USA. Electronic address: mwoola@lsuhsc.edu.
Abstract
BACKGROUND AND AIMS: The recombinant adeno-associated viral vector serotype 8 expressing the gain-of-function mutation of mouse proprotein convertase subtilisin/kexin type 9 (AAV8- PCSK9) is a new model for the induction of hypercholesterolemia. AAV8 preferentially infects hepatocytes and the incorporated liver-specific promoter should ensure expression of PCSK9 in the liver. Since tissue distribution of AAVs can differ between male and female mice, we investigated the differences in PCSK9 expression and hypercholesterolemia development between male and female mice using the AAV8-PCSK9 model. METHODS: Male and female C57BL/6 mice were injected with either a low-dose or high-dose of AAV8-PCSK9 and fed a high-fat diet. Plasma lipid levels were evaluated as a measure of the induction of hypercholesterolemia. RESULTS: Injection of mice with low dose AAV8-PCSK9 dramatically elevated both serum PCSK9 and cholesterol levels in male but not female mice. Increasing the dose of AAV8-PCSK9 threefold in female mice rescued the hypercholesterolemia phenotype but did not result in full restoration of AAV8-PCSK9 transduction of livers in female mice compared to the low-dose male mice. Our data demonstrate female mice respond differently to AAV8-PCSK9 injection compared to male mice. CONCLUSIONS: These differences do not hinder the use of female mice when AAV8-PCSK9 doses are taken into consideration. However, localization to and production of AAV8-PCSK9 in organs besides the liver in mice may introduce confounding factors into studies and should be considered during experimental design.
BACKGROUND AND AIMS: The recombinant adeno-associated viral vector serotype 8 expressing the gain-of-function mutation of mouseproprotein convertase subtilisin/kexin type 9 (AAV8- PCSK9) is a new model for the induction of hypercholesterolemia. AAV8 preferentially infects hepatocytes and the incorporated liver-specific promoter should ensure expression of PCSK9 in the liver. Since tissue distribution of AAVs can differ between male and female mice, we investigated the differences in PCSK9 expression and hypercholesterolemia development between male and female mice using the AAV8-PCSK9 model. METHODS: Male and female C57BL/6 mice were injected with either a low-dose or high-dose of AAV8-PCSK9 and fed a high-fat diet. Plasma lipid levels were evaluated as a measure of the induction of hypercholesterolemia. RESULTS: Injection of mice with low dose AAV8-PCSK9 dramatically elevated both serum PCSK9 and cholesterol levels in male but not female mice. Increasing the dose of AAV8-PCSK9 threefold in female mice rescued the hypercholesterolemia phenotype but did not result in full restoration of AAV8-PCSK9 transduction of livers in female mice compared to the low-dose male mice. Our data demonstrate female mice respond differently to AAV8-PCSK9 injection compared to male mice. CONCLUSIONS: These differences do not hinder the use of female mice when AAV8-PCSK9 doses are taken into consideration. However, localization to and production of AAV8-PCSK9 in organs besides the liver in mice may introduce confounding factors into studies and should be considered during experimental design.
Authors: T Vandendriessche; L Thorrez; A Acosta-Sanchez; I Petrus; L Wang; L Ma; L DE Waele; Y Iwasaki; V Gillijns; J M Wilson; D Collen; M K L Chuah Journal: J Thromb Haemost Date: 2006-09-26 Impact factor: 5.824
Authors: David B Wang; Robert D Dayton; Phillip P Henning; Cooper D Cain; Li Ru Zhao; Lisa M Schrott; Elysse A Orchard; David S Knight; Ronald L Klein Journal: Mol Ther Date: 2010-09-28 Impact factor: 11.454
Authors: Martin Maeng Bjørklund; Anne Kruse Hollensen; Mette Kallestrup Hagensen; Frederik Dagnaes-Hansen; Christina Christoffersen; Jacob Giehm Mikkelsen; Jacob Fog Bentzon Journal: Circ Res Date: 2014-03-27 Impact factor: 17.367
Authors: A S Plump; J D Smith; T Hayek; K Aalto-Setälä; A Walsh; J G Verstuyft; E M Rubin; J L Breslow Journal: Cell Date: 1992-10-16 Impact factor: 41.582
Authors: Maria M Xu; Antoine Ménoret; Sarah-Anne E Nicholas; Sebastian Günther; Eric J Sundberg; Beiyan Zhou; Annabelle Rodriguez; Patrick A Murphy; Anthony T Vella Journal: Am J Physiol Heart Circ Physiol Date: 2019-04-12 Impact factor: 5.125
Authors: Georgios Louloudis; Samuele Ambrosini; Francesco Paneni; Giovanni G Camici; Dietmar Benke; Jan Klohs Journal: Front Cardiovasc Med Date: 2021-09-22
Authors: Cassidy M R Blackburn; Robert M Schilke; Aimee E Vozenilek; Sunitha Chandran; Temitayo T Bamgbose; Brian N Finck; Matthew D Woolard Journal: Atherosclerosis Date: 2021-07-01 Impact factor: 6.847
Authors: Martin Schlegel; Monika Sharma; Emily J Brown; Alexandra A C Newman; Yannick Cyr; Milessa Silva Afonso; Emma M Corr; Graeme J Koelwyn; Coen van Solingen; Jonathan Guzman; Rubab Farhat; Cyrus A Nikain; Lianne C Shanley; Daniel Peled; Ann Marie Schmidt; Edward A Fisher; Kathryn J Moore Journal: Circ Res Date: 2021-07-22 Impact factor: 23.213